ClinicalTrials.gov TRIUMPH-1: A Master Protocol to Investigate the Efficacy and Safety of Retatrutide (LY3437943) Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (NCT05929066)
For patients with Long COVID and ME/CFS, who are often trapped in a state of chronic, systemic hyper-inflammation, this ability to downregulate pro-inflammatory cytokine cascades while simultaneously supporting targeted antiviral defenses makes L-Lysine a highly valuable therapeutic agent
These small, consistent changes, coupled with the GLP-1, have made a significant impact on my results
Any tapering approach should be guided by the patients indication for use, current dose, and clinical risk profile
We said Lets be competitors. I think people are starting to think we can start winning
Here are two ending thoughts: 1